Tailored Factor IX-Albumin Fusions: Dictating Hemostasis and Distribution in Hemophilia B

Article Impact Level: HIGH
Data Quality: STRONG
Summary of Nature Communications,https://doi.org/10.1038/s41467-025-62955-9 
Dr. Kristin Hovden Aaen et al.

Points

Researchers investigated engineering coagulation factor IX for improved or reduced type IV collagen binding, assessing its impact on pharmacokinetic properties when fused to human serum albumin.
Hyperactive features of FIX Padua and an extended plasma half-life from engineered HSA were confirmed in human FcRn expressing mice.
In hemophilia B mice, PaduaKA-HSAQMP showed minimal extravascular distribution and high initial plasma levels with a steep decay.
Conversely, PaduaKR-HSAQMP demonstrated increased extravascular distribution and a 3-fold longer functional half-life of 80 hours.
These findings suggest PaduaKA-HSAQMP and PaduaKR-HSAQMP could be used as hyperactive short- or long-term therapeutics for tailored hemophilia B replacement therapy.

Summary

This research investigated the effects of modifying factor IX (FIX) for altered type IV collagen (Col4) binding on its pharmacokinetic properties, particularly when fused to an engineered human serum albumin (HSAQMP) for enhanced neonatal Fc receptor (FcRn) engagement. The study confirmed the hyperactive characteristics of FIX Padua and the extended plasma half-life conferred by HSAQMP in human FcRn expressing mice. These findings support the potential for developing tailored hemophilia B (HB) replacement therapies.

In hemophilia B mice models, the PaduaKA-HSAQMP variant, engineered for reduced Col4 binding, exhibited negligible extravascular distribution and achieved the highest initial plasma levels, followed by the steepest decay. Conversely, the PaduaKR-HSAQMP variant, designed for increased Col4 binding, demonstrated enhanced extravascular distribution and a significantly prolonged functional half-life of 80 hours. This represents a 3-fold increase in functional half-life compared to other variants, suggesting distinct therapeutic applications.

The precise modulation of extravascular Col4 binding, achieved through specific amino acid substitutions at position 5 (K5A for reduced binding and K5R for strengthened binding), fundamentally alters the in vivo distribution and functional longevity of FIX-HSA fusion proteins. These findings propose that PaduaKA-HSAQMP could serve as a hyperactive short-term therapeutic, while PaduaKR-HSAQMP offers a long-term therapeutic option, paving the way for individualized hemophilia B treatment strategies.

Link to the article: https://www.nature.com/articles/s41467-025-62955-9

References

Aaen, K. H., Testa, M. F., Nilsen, J., Tarantino, R., Canepari, C., Benedusi, M., Benjakul, S., Nyquist-Andersen, M., Herigstad, M. L., Cantore, A., Valacchi, G., Sandlie, I., Bernardi, F., Pinotti, M., Branchini, A., & Andersen, J. T. (2025). Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties. Nature Communications, 16(1), 8433. https://doi.org/10.1038/s41467-025-62955-9